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Abstract: The application of induced pluripotent stem cell (iPSC) technologies in cell 
based strategies, for the repair of the central nervous system (with particular focus on the 
spinal cord), is moving towards the potential use of clinical grade donor cells. The ability 
of iPSCs to generate donor neuronal, glial and astrocytic phenotypes for transplantation is 
highlighted here, and we review recent research using iPSCs in attempts to treat spinal cord 
injury in various animal models. Also discussed are issues relating to the production of 
clinical grade iPSCs, recent advances in transdifferentiation protocols for iPSC-derived donor 
cell populations, concerns about tumourogenicity, and whether iPSC technologies offer any 
advantages over previous donor cell candidates or tissues already in use as therapeutic 
tools in experimental spinal cord injury studies. 
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1. Introduction 
Spinal cord injury (SCI) is characterised by damage to sensory and motor function, the extent of any 
functional loss dependent on the location, extent (severity) and type of injury (contusion vs. 
transection, incomplete vs. complete). Sensorimotor loss that results from a primary mechanical injury 
is a result of many interacting pathological factors, including: axonal damage, loss of neurons, 
activation of astrocytes and microglia, degeneration of oligodendrocytes, and demyelination [1]. The 
extent of this initial damage is significantly increased by ensuing secondary cascades of ischaemia, 
anoxia, generation of damaging free-radicals, lipid peroxidation, excitotoxicity, and immune-mediated 
and inflammatory events (e.g., cytokines), which can stimulate further cell death and tissue loss. A 
region of spreading degeneration rostral and caudal to the injury site, together with inhibitor molecule 
production, eventually leads to cavitation as well as a glial scar rich in, among other things, various 
types of chondroitin sulphate proteoglycans (CSPG) that are extremely inhibitory to axonal regrowth. 
Strategies to induce repair and promote functional (locomotor) recovery generally aim to reduce the 
extent of secondary damage and demyelination, promote the re-myelination of damaged (but still viable) 
axons, induce axonal repair and/or regeneration, and perhaps stimulate an endogenous stem cell 
response. For decades, extensive research has been conducted into clinically relevant cell 
transplantation strategies to either promote regeneration or to replace damaged/missing cell 
populations using: fibroblasts, peripheral nerve grafts and Schwann cell bridges, olfactory ensheathing 
glia (OEG), embryonic stem cells (ESCs), oligodendroglial progenitor cells (OPCs), adult neural 
precursor cells (NPCs) and neural stem cells (NSCs), autologous macrophages and mesenchymal 
precursor cells (MPCs) isolated from bone marrow stroma (BMSCs) (for reviews see [2–5]). More 
recently, the possibility of developing strategies that use induced Pluripotent Stem Cell (iPSC) 
technology to generate donor cell populations has gathered momentum. 
2. iPSCs as Neuronal and Glial Candidate Donor Populations 
To date, iPSCs have been directed to generate neural crest cells [6,7], peripheral sensory  
neurons [8], neural stem cells and their neuronal progenitors including specific neuronal subtypes such 
as dopaminergic neurons [9–17] glutamatergic neurons [18–21], GABAergic neurons [18,19,22], 
motor neurons [23–26,27–29] (see also Faravelli et al. 2014 for review of methodologies of induction 
into motor neurons [30]), retinal neurons [31–34], as well as astrocytes [35–38] and oligodendrocyte 
lineages [37,39–43]. iPSCs and their derivatives have been tested in various in vivo animal  
models of neurological/neurodegenerative disorders including Parkinson’s Disease [9–12,14,44], 
demyelination [37,39–43], retinal regeneration [32,33], stroke [45–48] and peripheral nerve  
regeneration [7] as well as others (see [49,50]). These studies provide proof-of-principle that iPSCs can 
be successfully differentiated in vitro to yield a desired progeny that, if necessary, can be effectively 
subjected to ex vivo gene therapy [51,52] and then transplanted with similar outcomes to other 
pluripotent ESC therapies [53–56]. 
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3. iPSCs in Spinal Cord Injury 
Despite a rapid increase in iPSC-based studies in recent years, currently there is only a small  
number of published preclinical studies describing the in vivo use of iPSCs in mouse [57–59],  
rat [36,50,57–62] or simian [37,60–62] models of SCI, or sub-dural parenchymal injections into  
non-injured rats [63]. 
Of these studies, rodent moderate contusion injuries were almost all made at the thoracic level  
(T9–T10) using the Infinite Horizon Impactor device (delivering 60–70 kDyne forces for mice and  
200 kDyne force for rat). An exception was a study that used C4 contusions using the Ohio State 
Injury Device [61], and Lu et al. [60] recently used C5 lateral hemisections in rats. Simian contusions 
have to date been more severe (17 g 50 mm drop at C5 using the NYU impactor [37] or a 50 g 10 mm 
drop at T9 [62]). All published studies using contusive SCI (apart from [62]) have reported neuronal, 
glial and astrocytic marker expression within or near the lesion after transplantation, with two groups 
reporting differentiation of donor cells into at least one or all these various cell types [37,50,58–63].  
These studies used iPSC donor cells that were pre-differentiated into either neurospheres (NS) [58,59], 
neural precursor cells (NPCs) [61,63], neural stem cells (NSCs) [60–62] astrocytes [36] or 
undifferentiated iPSCs [50]. Sareen et al. [63] found that NPCs derived from iPSCs showed variability in 
differentiation phenotype and survival characteristics following transplantation, but migrated and 
integrated within the uninjured cord. Superparamagnetic iron oxide labelled iPSC-derived NSCs were 
tracked non-invasively using magnetic resonance imaging (MRI) from the cell injection sites in monkeys 
that extended progressively to the lesion regions [62]. Transplanted iPSC-derived NPCs after early 
chronic cervical SCI were shown to form neurons, astrocytes and oligodendrocytes at 8 weeks  
post transplantation, however importantly failed to promote functional recovery in forelimb  
behavioural tasks. 
Whilst murine SCI studies using iPSC-derived donor cells showed functional improvements, others 
have reported no significant differences in morphological or functional outcomes in another acute 
moderate contusion SCI model in rats [36,50,60]. Lu et al. [60] reported that 3 months after 
transplantation, surviving human iPSC-derived NSCs from an 86 year old donor male exhibited 
extraordinarily long distance axonal growth with the host rat spinal cord, with human axons growing 
rostral and caudal to the lesion site and forming synaptic structures with host neurons and dendrites. 
Such extensive growth of immature human cells within the rodent central nervous system (CNS) is 
similar to that obtained many years ago using grafts of human fetal tissue and neuroblasts (e.g., [64]). 
In the iPSC study, host axons grew into the donor grafts and also formed synaptic structures, again 
similar to previous work that used donor fetal material of some kind (e.g., [65]). Taken together the 
new iPSC work confirms that even in the injured adult CNS it is possible, in some cases, to overcome 
the inhibitory environment of the lesion and elicit substantial regenerative growth and circuit 
construction. The grafting technique used by Lu et al. 2014 [60] involved a cocktail of growth factors 
(including brain-derived neurotrophic factor, neurotrophin-3, platelet-derived growth factor-AA, 
insulin-like growth factor-1, epidermal growth factor, basic fibroblast growth factor, acidic fibroblast 
growth factor, glial cell line-derived neurotrophic factor, hepatocyte growth factor, and calpain 
inhibitor in a fibrin matrix) that previously was shown by the same group to promote robust 
engraftment of donor (non-iPSC derived) NSCs, extensive integration with host tissue, long-distance 
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outgrowth of axons from grafts and extensive ingrowth of host axons into the graft after acute thoracic 
(T3) SCI [66]. 
Significant functional improvement was reported in the initial NSC study [66]; however more 
recently, Lu et al. (2014) in a C5 lateral hemisection study [60], reported no measurable improvement 
in forelimb function in host rats despite the use of the same growth cocktail, extensive axonal 
outgrowth and cellular integration. The authors suggest that the injury type itself, the rate of maturation 
of donor cells (so that insufficient numbers of mature neurons were present to support recovery), 
inadequate myelination, undesirable ectopic projections and/or insufficient expression of 
neurotransmitters could account for the discrepancy between the functional recovery observed  
between the two studies. Whilst the extent of hindlimb versus forelimb recovery may vary depending 
on the type and complexity of restored or adapted neural circuitry [60], it is also important to note that 
independent researchers that attempted to replicate this study (as part of the NIH “Facilities of 
Research Excellence-Spinal Cord Injury” project to support independent replication) revealed 
conflicting data relating to ingrowth of host axons into the grafts and behavioural outcomes [67]. 
Overall, these are very important and influential studies, but the extent to which reported differences 
also reflect, for example, variation in surgical procedures, the individual contributions of factors in the 
growth cocktail [68], or differences in the nature and response of the donor cell type after 
transplantation, needs to be established, and future work should yield valuable information in  
this regard. 
The approach of using restricted or individual populations of donor cells in the hope of achieving 
regrowth or repair leading to morphological improvements and functional restoration has some 
limitations. The ability of a wide variety of adult somatic (e.g., Schwann cells, olfactory ensheathing 
glia) and precursor/progenitor (e.g., NPCs, NSCs, OPCs, MPCs) cells to undergo directed 
differentiation and perform functionally and phenotypically as required in vitro has not always been 
reproduced when cells are transplanted into the inhibitory environment of the injured spinal cord  
in vivo. Perhaps these well characterised donor cells that meet necessary research requirements in a 
wide variety of controlled settings other than the injured spinal cord, simply fail to “perform” in animal 
models in vivo because of the antagonistic, often inflammatory environment they find themselves in 
after transplantation [69]. Those donor cells that eventually survive the host immune response may be 
unable to successfully respond to the new and dynamic myriad of both inhibitory and growth 
promoting stimuli of the host’s injured spinal cord that is known to occur in a temporal and spatial 
fashion after trauma. Simply, the “correct language” that equipped the donor cells with the ability to 
perform all of those functions observed under controlled conditions in vitro, is no longer able to be 
understood or followed in vivo. Perhaps by using combined populations of adult stem cell-derived 
oligodendrocyte, astrocyte and neuronal precursor cells in the same relative proportions as those found 
within the uninjured (normal) spinal cord, we may achieve a phenotypic state that will allow enhanced 
plasticity and optimal repair/regrowth. 
It is crucial to ensure that appropriate cell controls are used in preclinical SCI studies to evaluate the 
extent of contribution of different cell phenotypes to the morphological and functional outcomes 
observed after treatment. This applies to any small populations of incompletely reprogrammed donor 
cells and/or incompletely pre-differentiated donor iPSCs. Whilst the studies mentioned may suggest 
that improved outcomes were observed in mouse but not necessarily in rat models of SCI, the disparity 
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in overall results from these very limited number of studies suggest that iPSC-based therapy in SCI 
warrants more extensive and thorough testing. Ideally, research in this area should be conducted using 
clinically relevant injury regimes in at least mouse and rat models as outlined in the recommendations 
and guidelines developed by the International Campaign for Cures of Spinal Cord Injury Paralysis 
(ICCP) [70] (see also [71,72]). Experimental studies in larger species (e.g., cats and primates) with  
an ascending and descending tract configuration more similar to the human [73], and capable of more 
complex sensorimotor behaviors, should also be undertaken. In addition, it may be important to 
include more relevant control donor cell types, such as cells that have been freeze-thawed. 
4. Conclusions 
There is a clear need to develop a gold standard positive control for use of stem cells in animal 
models of SCI, to determine the validity and reliability for future clinical application. It is most likely 
that stem cell therapy alone will not work for SCI, but will require new efforts to combine stem cell 
therapy with other treatments perhaps, such as bio-scaffolds, immune response modifications, and the 
timing of the use of different treatments, although the consensus at present is “the earlier the better”. 
The threat of tumorigenicity remains to be fully addressed. In SCI studies that used iPSC-derived 
donor cells, “unsafe” murine iPSC-derived donor cells, but not “safe” donor cells, produced  
teratomas [59], although another study did not report such teratoma formation [36]. Of those studies 
using human iPSC-derived donor cells, one study did not report on teratoma formation [57], whilst 
others reported no evidence of tumour formation [37,50,58,60–63]. For clinical applications, donor 
cells must be grown in animal cell-free and serum-free conditions and derivation of the first hESC line 
with these properties has been a major advance for clinical applications of stem cell therapy [74]. 
Despite their highly similar expression of genes related to pluripotency and development, there is 
evidence that iPSCs may occupy a distinct pluripotent “state” from ESCs [50,75], and therefore iPSCs 
may not have the same capacity as ESCs to generate the whole spectrum of region-specific neural 
progenitors and functional neuronal subtypes for SCI therapies (and other CNS disorders). 
Nevertheless, the approaching capacity to produce clinical grade iPSCs, together with advances in the 
efficiency of transdifferentiation protocols for iPSCs into the required phenotypes, marks a potential 
focus toward the use of iPSC-derived donor cell populations for cell based therapies. If hESC-derived 
OPCs can be used in SCI trials (Geron), this should surely herald the addition of the clinical grade 
iPSCs to the potential repertoire of donor cell candidates for SCI and other neurotrauma related 
therapies, as long as they are conducted in accordance with Good Clinical Practise (GCP) and the 
associated regulatory directives. 
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